Dipeptidyl peptidase-4: difference between revisions
Diff·revision 20 → 21·13:17, 10 Jul 2025
Difference between revision 20 and revision 21 of Dipeptidyl peptidase-4. 3 lines changed; the page grew by 554 bytes.
| Revision 20 — 21:07, 14 Jun 2025 EmptyingElke (talk) add the counter-regulatory glucagon point, sourced 6,468 bytes +446 | Revision 21 — 13:17, 10 Jul 2025 AmylinAmos (talk) British spelling per PP:MOS 7,022 bytes +554 | ||
|---|---|---|---|
| 51 | DPP-4 matters to anyone measuring incretin concentrations. Blood drawn without a DPP-4 inhibitor in the tube continues to degrade GLP-1 ''ex vivo'', and comparisons between studies that did and did not add an inhibitor at collection are not meaningful. Total-GLP-1 assays that detect both intact and truncated forms give systematically higher and less interpretable numbers than intact-specific assays.{{r|holst2007}} | 51 | DPP-4 matters to anyone measuring incretin concentrations. Blood drawn without a DPP-4 inhibitor in the tube continues to degrade GLP-1 ''ex vivo'', and comparisons between studies that did and did not add an inhibitor at collection are not meaningful. Total-GLP-1 assays that detect both intact and truncated forms give systematically higher and less interpretable numbers than intact-specific assays.{{r|holst2007}} |
| 52 | 52 | ||
| + | 53 | The same consideration applies to stability work on the therapeutic peptides themselves. A DPP-4-resistant analogue is resistant to that specific enzyme, not to proteolysis in general, and stability in plasma is not evidence of stability in a reconstituted vial, where [[Deamidation|deamidation]] and [[Peptide aggregation|aggregation]] rather than proteolysis are the degradation routes that matter.{{r|usp1503}} | |
| + | 54 | ||
| 53 | == References == | 55 | == References == |
| 54 | {{reflist}} | 56 | {{reflist}} |
| ⋮ | ⋮ | ||
| 56 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> | 58 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> |
| 57 | <ref name="knudsen2019">Knudsen LB, Lau J. "The discovery and development of liraglutide and semaglutide." ''Frontiers in Endocrinology'' 10:155 (2019). PMID 31031702.</ref> | 59 | <ref name="knudsen2019">Knudsen LB, Lau J. "The discovery and development of liraglutide and semaglutide." ''Frontiers in Endocrinology'' 10:155 (2019). PMID 31031702.</ref> |
| + | 60 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 58 | 61 | ||
| 59 | == See also == | 62 | == See also == |